RE:Some Random Thoughts...............RPINVESTOR wrote: 1. With the last two private placement offerings,the last of the promises to Replicel Shareholders has been broken by CEO LB. It had been my hope that keeping the share count down would have given the long holding share owners a reasonable exit price. This has been shattered with these desperate clearance sales.
2. In my opinion, CEO LB is completely unsuited for his job. He seems to think that being an entrepreneur is buying a 90 day certificate of deposit at a local bank. Why is it that Theranos could raise so much money, yet Replicel (with also a game changing technology) has struggled to raise enough money in earlier stock issues to just cover past debts and modestly incease cash on hand? Clearly, the right people were not made aware of the potential of the Company.
3. The terms of the deal with YOFTO (in my opinion) have been a significant factor in Replicel's current stock price. There was obviously an agreement that YOFTO would not start their Phase 2 programs until the dermal injector was approved for use. It would have been better if the parties had agreed to this condition for Phase 3 only (Remember - Shiseido did their Phase 2 trials without the injector.). If this had been done, the Phase 2 trials would now be completed.
4. If Replicel wins the Arbitration, I believe that it is time to get tough with Shiseido. They have done their best to make life difficult for Replicel. It is clear that a business relationship with them is no longer possible. Following the Arbitration verdict, I would give Shiseido 30 days to agree to a $750 million (Canadian) buyout of Replicel. If they do not agree, I would put them in the rear view mirror forever.
RPINVESTOR I agree that the lack of activity by Yofoto after 4 years of the Contract being signed I think is more involved than waiting for the Dermal Injector. They removed their Director from the Board a number of years ago. I sense that Yofoto quickly became disillusioned with Replicel and their false promises just like Shiseido.
In the last few years these PP's have as you mentioned diluted the share count considerably. I quick count is that it has more than doubled the share count, which I think is one of the key factors in keeping the share price at this level.
The lack of institutional investors and big Pharma is mainly due to the fact that non of their assets have been proven to work and that includes the Dermal Injector. We read lots of tweets regarding the Dermal Injector but yet after years it still has not been submitted for approval.....why?
If Replicel wins the Arbitration which I think they will the company needs to be in the hands of a company with deep R & D pockets. I like your number but I would be even happy with $200,000,000 which would be approx. $4.00/share